Ignite Creation Date:
2025-12-24 @ 11:48 PM
Ignite Modification Date:
2026-02-20 @ 12:36 PM
Study NCT ID:
NCT02268851
Status:
COMPLETED
Last Update Posted:
2024-11-15
First Post:
2014-10-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-11
Start Date Type:
None
Primary Completion Date:
2018-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10
Completion Date Type:
ACTUAL
First Submit Date:
2014-10-16
First Submit QC Date:
None
Study First Post Date:
2014-10-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-05-12
Results First Submit QC Date:
None
Results First Post Date:
2020-06-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-11
Last Update Post Date:
2024-11-15
Last Update Post Date Type:
ACTUAL